Bevacizumab biosimilar - Centus Biotherapeutics

Drug Profile

Bevacizumab biosimilar - Centus Biotherapeutics

Alternative Names: FKB-238

Latest Information Update: 24 Jun 2016

Price : $50

At a glance

  • Originator Fujifilm Kyowa Kirin Biologics
  • Developer Centus Biotherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 15 Jun 2016 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in Spain (IV) (EudraCT2015-004104-33)
  • 24 Jul 2015 Fujifilm Kyowa Kirin Biologics and AstraZeneca form a joint venture for the development and commercialisation of bevacizumab biosimilar for the treatment of Solid tumours
  • 01 Nov 2014 Phase-I clinical trials in Solid tumours in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top